Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Mefexamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mefexamide SCHEMBL126334 | 0.99 | CYP1A2 (1.00) | CYP3A4CYP1A2CYP2D6ALDH1A1PTPN1 | |
| Mefexamide SCHEMBL1650022 | 0.96 | CYP1A2 (0.95) | CYP3A4CYP1A2CYP2D6ALDH1A1PTPN1 | |
| Clofexamide SCHEMBL365077 | 0.88 | CYP3A4 (0.78) | CYP3A4CYP1A2CYP2D6ALDH1A1KDM4E | |
| Clofexamide SCHEMBL1604514 | 0.86 | CYP1A2 (0.78) | CYP3A4CYP1A2CYP2D6ALDH1A1KDM4E | |
| Hydrochloric Acid SCHEMBL11539142 | 0.84 | CYP3A4 (0.73) | CYP3A4CYP1A2CYP2D6KDM4ESMN1; SMN2 | |
| SCHEMBL7002893 | 0.83 | CYP1A2 (0.73) | CYP3A4CYP1A2CYP2D6ALDH1A1MAPK1 | |
| SCHEMBL10379993 | 0.78 | LMNA (0.68) | CYP3A4CYP1A2CYP2D6ALDH1A1MAPK1 | |
| Formic Acid SCHEMBL6325576 | 0.77 | CYP1A2 (0.64) | CYP3A4CYP1A2CYP2D6ALDH1A1PTPN1 | |
| SCHEMBL7701481 | 0.76 | CYP1A2 (0.63) | CYP3A4CYP1A2CYP2D6ALDH1A1PTPN1 | |
| SCHEMBL7266793 | 0.76 | CYP1A2 (0.62) | CYP3A4CYP1A2CYP2D6ALDH1A1PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-19 | — | — | US | claimed |
| EP-4025302-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-13 | — | — | EP | claimed |
| WO-2021046438-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-11 | — | — | WO | claimed |
| WO-2025133679-A1 | COMPOUNDS AND COMPOSITION FOR DNA PROTECTION | ASSOCIAÇÃO PARA DESENVOLVIMENTO DO CENTRO ACADÉMICO DE INVESTIGAÇÃO E FORMAÇÃO BIOMÉDICA DO ALGARVE, AD-ABC (PT) | 2025-06-26 | — | — | WO | disclosed |
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-01-19 | — | — | US | disclosed |
| EP-4025302-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114340733-A | Regeneration of connective tissue function and phenotype by Npas2 inhibition | 加利福尼亚大学董事会 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021046438-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-11 | — | — | WO | disclosed |
| US-10004701-B2 | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (US) | 2018-06-26 | — | — | US | disclosed |
| EP-2806034-B1 | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject | ROUSSY INST GUSTAVE (FR) | 2017-06-28 | — | — | EP | disclosed |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | UNIVERSITY OF ROCHESTER (US) | 2017-03-09 | — | — | US | disclosed |
| US-20130023488-A1 | METHODS AND COMPOUNDS FOR REDUCING INTRACELLULAR LIPID STORAGE | THE GENERAL HOSPITAL CORPORATION (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012007783-A1 | KITS AND METHODS FOR DETECTING THE ABILITY TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT | INSTITUT GUSTAVE ROUSSY (FR) | 2012-01-19 | — | — | WO | disclosed |
| WO-2011131472-A1 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT | INSTITUT GUSTAVE ROUSSY (FR) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011131246-A1 | COMPOUNDS AND USES THEREOF TO INDUCE AN IMMUNOGENIC CANCER CELL DEATH IN A SUBJECT | INSTITUT GUSTAVE ROUSSY (FR) | 2011-10-27 | — | — | WO | disclosed |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100304998-A1 | Chemical Proteomic Assay for Optimizing Drug Binding to Target Proteins | MARQUETTE UNIVERSITY (US) | 2010-12-02 | — | — | US | disclosed |
| EP-0804239-B1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1999-09-15 | — | — | EP | disclosed |
| EP-0804239-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | Riga, Dan (RO) | 1997-11-05 | — | — | EP | disclosed |
| WO-1995033486-A1 | ANTI-STRESS, ANTI-IMPAIRMENT AND ANTI-AGING DRUG AND PROCESS FOR MANUFACTURING THEREOF | RIGA DAN (RO) | 1995-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230013402-A1 | REGENERATING FUNCTIONS AND PHENOTYPES OF CONNECTIVE TISSUE THROUGH NPAS2 SUPPRESSION | PER2, NCBP2, NOTCH1 | GAA 4630/4885CYP3A4 4867/4885CYP1A2 4337/4885 |
| US-20100305326-A1 | Chemical Fragment Screening and Assembly Utilizing Common Chemistry for NMR Probe Introduction and Fragment Linkage | CYFIP2, RPS27A, FRS2 | GAA 2825/4885CYP3A4 2560/4885CYP1A2 3277/4885 |
| US-20170065540-A1 | METHODS AND COMPOSITIONS FOR TREATING INFECTION | MMP8, IFNG, MPO | GAA 1194/4885CYP3A4 2777/4885CYP1A2 2305/4885 |
| US-10004701-B2 | Methods and compositions for treating infection | MMP8, IFNG, MPO | GAA 1194/4885CYP3A4 2777/4885CYP1A2 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.